Live from ash 2024 | ascentage pharma releases updated data of bcl-2 inhibitor lisaftoclax in mds that demonstrates potential clinical benefits and favorable safety

Rockville, md. and suzhou, china , dec. 10, 2024 /prnewswire/ -- ascentage pharma (6855.hk), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the follow-up safety and efficacy data of the company's investigational bcl-2 selective inhibitor, lisaftoclax (apg-2575), in combination with azacitidine (aza) for the treatment of patients with myelodysplastic syndrome (mds), in a poster presentation at the 66th american society of hematology (ash) annual meeting, taking place in san diego, ca, the united states.
ASH Ratings Summary
ASH Quant Ranking